Products for Research Use Only

BChE/p38-α MAPK-IN-1

CAT: 0804-HY-175655Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-175655Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine -induced cognitive impairment, as well as alleviates LPS (HY-D1056) -induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation[1].
CAS Number
3077831-11-6
UNSPSC
12352100
Target
Cholinesterase (ChE) ; Interleukin Related; p38 MAPK
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
O=C(C1=CC2=C(C=C1CC3=CC=C(F)C=C3F)C=NN2CC4CCCCC4)NCCN(C)C
Molecular Formula
C26H32F2N4O
Molecular Weight
454.56
References & Citations
[1]Ferjančič Benetik S, et al. Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors. J Med Chem. 2025 Aug 28;68 (16) :17378-17411.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BChE; p38α